Considering non-modifiable factors, triple-negative (OR 1.83, 95% CI 1.39-2.41) or HER2 positive BC (OR 1.73, CI 1.20-2.49) was associated with more advanced stage at diagnosis (Figure 2), whereas tumor grade did not significantly affect the disease stage. Here, ERBB2 is linked to breast cancer.